Obviously, the field of immune-oncology has been one of the great success stories in our field over the last five years, based on our molecular understanding of the mechanisms of immune tolerance (or checkpoints) and how to disrupt that. Not only has ASCO declared Checkpoint Inhibition (as well as cellular-based immunotherapy) the “Advance of the Year,” the Nobel Committee awarded this year’s Prize to Drs. Allison and Honjo for their fabulous observations that led to these great breakthroughs.
Has Tecentriq earned a role in treatment of triple-negative breast cancer? Here is what experts say
Former member of the FDA Oncologic Drugs Advisory Committee
YOU MAY BE INTERESTED IN
The National Coalition for Cancer Survivorship has provided the Cancer History Project with a rich archive of its newsletters: the NCCS Networker, volumes 1-11.